Neuralink's implants in today's trials mostly record from the brain. Blindsight would work in the other direction, delivering input to the brain through electrical stimulation. The N1 implant, with 1,024 electrodes on flexible threads, has chips that can both record and stimulate. Blindsight would target the visual cortex, bypassing damaged eyes or optic nerves.
Elon Musk announced Blindsight in 2024, and it received an FDA Breakthrough Device Designation in September of that year, as Neuralink announced. Musk has said it could work even for people blind from birth, as long as their visual cortex is intact. Neuralink has not yet started a human Blindsight trial; its visual prosthesis page invites people to join its registry to be told when US trials launch.
Neuralink has not published Blindsight's stimulation settings, frame rate, power use, or resolution, so the steps below describe the design in general terms.
A camera, likely mounted on glasses, would capture the scene in real time. Software on a paired phone or computer would simplify the image to match what the implant can show. Musk has compared the first results to early Atari graphics.
Software would convert the simplified image into commands for individual electrodes. The visual cortex is laid out like a map of the visual field, so neighboring electrodes would correspond to neighboring points in the scene. Stimulating a small group of neurons produces a phosphene, a spot of light that the person perceives without any light reaching the eye. Many phosphenes together could form a rough image.
The patterns would travel wirelessly from the external device to the implant, the same way Neuralink's current implants exchange data with a paired computer over Bluetooth. The implant has no wires through the skin, which reduces the risk of infection.
The implant's chips would deliver small, balanced electrical pulses through each electrode. Recording channels could check how neurons respond and help adjust the stimulation over time. The robot would place the threads during surgery, as it does in Neuralink's current trials.
The brain would have to learn to read the phosphene patterns as useful images, and researchers expect that skill to improve with practice. Musk has said later versions could exceed normal human vision, adding infrared or ultraviolet perception. None of this has been tested in people yet.
Neuralink reported zero serious device-related adverse events across its Telepathy participants as of January 2026. Internal projections reported by Bloomberg targeted Blindsight approval by 2030 and 20,000 implants a year by 2031.
This article was first published in October 2025 and corrected in October 2026; the latest patient count is on the patient table.